Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara; Comparisons and combinations

Biological Chemistry

Volumn 380, Issue 3, 1999, Pages 299-303

  Gilbert, Sarah C ^a   Schneider, Jörg ^b   Plebanski, Magdalena ^b   Hannan, Carolyn M ^b   Blanchard, Tom J ^c   Smith, Geoff L ^c   Hill, Adrian V S ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cytotoxic T cells; DNA vaccine; Malaria; Modified vaccinia virus Ankara; Virus like particles

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; MALARIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; MALARIA; MOUSE; NONHUMAN; PARASITE IMMUNITY; PLASMODIUM BERGHEI; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS PARTICLE;

ANIMALIA; ANKARA; PLASMODIUM BERGHEI; VACCINIA; VACCINIA VIRUS;

EID: 0033005077     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.1999.041     Document Type: Article

References (27)

1. Adams, S.E., Dawson, K.M., Gull, K., Kingsman, S.M., and Kingsman, A.J. (1987). The expression of hybrid HIV:Ty virus-like particles in yeast. Nature 329, 68-70.
2. Allsopp, C.E., Plebanski, M., Gilbert, S., Sinden, R.E., Harris, S., Frankel, G., Dougan, G., Hioe, C., Nixon, D., Paoletti, E., Layton, G., and Hill, A.V. (1996). Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 26, 1951-1959.
3. Antoine, G., Scheiflinger, F., Dorner, F., and Falkner, F.G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.
4. Blanchard, T.J., Alcami, A., Andrea, P., and Smith, G.L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79, 1159-1167.
5. Chakrabarti, S., Brechling, K., and Moss, B. (1985). Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5, 3403-3409.
6. Doolan, D.L., Khamboonruang, C., Beck, H.P., Houghten, R.A., and Good, M.F. (1993). Cytotoxic T lymphocyte (CTL) low-responsivenessto the Plasmodium falciparum circumsporozoite protein in naturally-exposed endemic populations: Analysis of human CTL response to most known variants. Int. Immunol. 5, 37-46.
7. Gilbert, S.C., Plebanski, M., Harris, S.J., Allsopp, C.E., Thomas, R., Layton, G.T., and Hill, A.V. (1997). A protein particle vaccine containing multiple malaria epitopes. Natl. Biotechnol. 15, 1280-1284.
8. Good, M.F., Kumar, S., and Miller, L.H. (1988). The real difficulties for malaria sporozoite vaccine development: nonresponsiveness and antigentic variation. Immunol. Today 9, 351-355.
9. Hanke, T., Blanchard, T.J., Schneider, J., Ogg, G.S., Tan, R., Becker, M., Gilbert, S.C., Hill, A.V., Smith, G.L., and McMichael, A. (1998). Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J. Gen. Virol. 79, 83-90.
10. Hill, A.V., Allsopp, C.E., Kwiatkowski, D., Anstey, N.M., Twumasi, P., Rowe, P.A., Bennett, S., Brewster, D., McMichael, A.J., and Greenwood, B.M. (1991). Common west African HLA antigens are associated with protection from severe malaria. Nature 352, 595-600.
11. Lalvani, A., Aidoo, M., Allsopp, C.E.M., Plebanski, M., Whittle, H.C., and Hill, A.V.S. (1994). An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum. Res. Immunol. 145, 461-468.
12. Layton, G.T., Harris, S.J., Gearing, A.J., Hill Perkins, M., Cole, J.S., Griffiths, J.C., Burns, N.R., Kingsman, A.J., and Adams, S.E. (1993). Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J. Immunol. 151, 1097-1107.
13. Leong, K.H., Ramsay, A.J., Morin, M.J., Robinson, H.L., Boyle, D.B., and Ramshaw, I.A. (1995). Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowlpox viruses. In: Vaccines 95, F. Brown, H. Chanock and E. Norrby, eds. (Cold Spring Harbor, N.Y., USA: Cold Spring Harbour Laboratory Press), pp. 327-331.
14. Lockyer, M.J., Marsh, K., and Newbold, C.I. (1989). Wild isolates of Plasmodium falciparum show extensive polymorphism in T cell epitopes of the circumsporozoite protein. Mol. Biochem. Parasitol. 37, 275-280.
15. + T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. 90, 5214-5218.
16. Mackett, M., Smith, G.L., and Moss, B. (1984). General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49, 857-864.
17. Mayr, A., Stickl, H., Muller, H.K., Danner, K., and Singer, H. (1978). The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. [B] 167, 375-390.
18. Miller, L.H., and Hoffman, S.L. (1998). Research toward vaccines against malaria. Nat. Med. 4, 520-524.
19. Plebanski, M., Gilbert, S.C., Schneider, J., Hannan, C.M., Layton, G., Blanchard, T., Becker, M., Smith, G., Butcher, G., Sinden, R.M., and Hill, A.V.S. (1998). Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur. J. Immunol. 28, 4345-4355.
20. Romero, P., Maryanski, J.L., Corradin, G., Nussenzweig, R.S., Nussenzweig, V., and Zavala, F. (1989). Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341, 323-326.
21. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397-402.
22. Sutter, G., and Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. 89, 10847-10851.
23. Sutter, G., Wyatt, L.S., Foley, P.L., Bennink, J.R., and Moss, B. (1994). A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032-1040.
24. Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J.C., Cox, W.I. et al. (1992). NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232.
25. Tine, J.A., Lanar, D.E., Smith, D.M., Wellde, B.T., Schultheiss, P., Ware, L.A. et al. (1996). NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64, 3833-3844.
26. Wizel, B., Houghten, R.A., Parker, K.C., Coligan, J.E., Church, P., Gordon, D.M., Ballou, W.R., and Hoffman, S.L. (1995). Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J. Exp. Med. 182, 1435-1445.
27. Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., and Felgner, P.L. (1990). Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468.